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ABSTRACT
In contrast to the negligible expression of the immunomodulating protein CD70 
in normal tissue, we have demonstrated constitutive overexpression of CD70 on tumor 
cells in a subset of primary non-small cell lung cancer (NSCLC) biopsies. This can be 
exploited by CD70-targeting antibody-dependent cellular cytotoxicity (ADCC)-inducing 
antibodies. Early clinical trials of these antibodies have already shown promising 
results in CD70-positive malignancies.
In this study, we explored the potential of cisplatin to induce CD70 expression 
in NSCLC. Using real-time measurement tools, we also assessed the efficacy of a 
combination regimen with cisplatin and anti-CD70 therapy under normoxia and 
hypoxia. We identified an induction of CD70 expression on lung cancer cells upon 
low doses of cisplatin, independent of oxygen levels. More importantly, the use of 
cisplatin resulted in an enhanced ADCC-effect of anti-CD70 therapy. As such, this 
combination regimen led to a significant decrease in lung cancer cell survival cell 
survival, broadening the applicability the applicability of CD70-targeting therapy.
 This is the first study that proves the potential of a combination therapy with 
cisplatin and CD70-targeting drugs in NSCLC. Based on our data, we postulate that this 
combination strategy is an interesting approach to increase tumor-specific cytotoxicity 
and reduce drug-related side effects.
                                                               Research Paper
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INTRODUCTION
Non-small cell lung cancer (NSCLC) retains its 
position as the most lethal type of cancer worldwide with 
around 1.3 million deaths each year and a marginally 
improving 5-year overall survival rate which remains below 
20% [1]. These data point towards the continued need for 
new therapeutic modalities. Recent insights into the biology 
of the immune response have led to a wave of clinical trials 
involving immunotherapy for lung cancer. Nonetheless, the 
immune suppressive and heterogeneous nature of this tumor 
generates variable success rates of immunotherapy in NSCLC 
patients, leaving room leaving room for improvement.
The expression of CD70, a member of the tumor 
necrosis factor family (TNF), is normally restricted to 
activated T and B cells and mature dendritic cells [2]. 
In contrast, we have previously revealed constitutive 
overexpression of CD70 on malignant cells in 16% of 
NSCLC tumor specimens [3]. Since CD70 is absent on 
normal epithelial tissue, the overexpression on tumor 
cells can be safely exploited by CD70-targeting antibody-
dependent cellular cytotoxicity (ADCC)-inducing 
antibodies, such as ARGX-110 [4]. Furthermore, it 
has been described that tumor-specific upregulation of 
CD70, through its unique receptor CD27, can facilitate 
immune evasion by increasing the proliferation of 
suppressive regulatory T cells, inducing T cell apoptosis 
and skewing T cells towards a T cell exhaustion profile 
[5–8]. Although we believe that anti-CD70 therapy 
holds great potential as monotherapy, this strategy 
would only be applicable to patients with CD70-positive 
tumors. Recently, the immunomodulatory properties of 
chemotherapy in combination with immunotherapy have 
been demonstrated [9]. Although chemotherapy has long 
been considered immune suppressive, recent studies have 
shown that in addition to its direct cytotoxic effects on 
cancer cells, certain chemotherapeutics can elicit changes 
in the tumor microenvironment that render cells more 
sensitive to an efficient immune cell attack [10]. In the 
present study, we evaluated a new combinatorial strategy 
with cisplatin (CDDP), first-line treatment in NSCLC, to 
maximize the efficacy of anti-CD70 therapy. We examined 
the induction of CD70 expression upon CDDP treatment 
in vitro and in vivo. We further evaluated the ADCC effect 
and immune stimulatory potential of anti-CD70 therapy 
(aCD70) upon sequential treatment with low-doses of 
CDDP. Finally, we assessed the therapeutic efficacy of 
the combination regimen under hypoxic conditions as 
regions within the tumor with different oxygen levels often 
characterize therapy resistance. 
RESULTS
Dose-response analysis of CDDP in NSCLC cell 
lines 
The cytotoxicity of CDDP monotherapy was 
assessed in a panel of five NSCLC cell lines, varying 
in genetic aberrations and histological subtype 
(Supplementary Table 1). Cells were treated with CDDP 
(0–20 µM) for 24 h and chemosensitivity was assessed 
by the Sulforhodamine-B assay. LUDLU-1 (IC50: 
5.46µM ± 0.93 µM) was most sensitive to treatment, 
followed by NCI-H1650 (IC50: 6.51 µM ± 0.46 µM). 
NCI-H1975 (IC50: 19.34µM ± 1.72 µM) and HCC827 
(IC50: 15.95 µM ± 1.37 µM) cells were most resistant 
to CDDP treatment (Figure 1). Because dose-response 
analysis of A549 cells (IC50: 10.04 µM ± 0.72 µM) was 
in-between our panel of NSCLC cell lines, we considered 
the doses equivalent to 20% (3.5 µM), 40% (7 µM) and 
60% (13 µM) of CDDP-induced growth inhibition in the 
A549 cells as respectively low, medium and high doses. 
Figure 1: Dose-response curve of CDDP in NSCLC cell lines. Survival curve after 24 h of treatment with CDDP (0–20 mM) in 
the NCI-H1975, HCC827, A549, NCI-H1650 and LUDLU-1 cells.
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CDDP induces/increases CD70 expression on 
protein and mRNA level
To analyze the impact of CDDP treatment on CD70 
expression, 3 NSCLC cell lines (NCI-H1650, A549, 
NCI-H1975) were selected out of the panel of NSCLC 
cell lines, based on their aberrations in CD70 expression 
levels (CD70-, CD70+ and CD70++) by flow cytometry 
and screened for membranous CD70 expression levels 
in response to CDDP treatment. Cells were treated for 24 
h with vehicle (0 µM), low (3.5 µM), medium (7 µM) 
or high (13 µM) doses of CDDP (Figure 1). Thereafter, 
CD70 protein levels were assessed at different time points 
(1 h, 6 h, 24 h, 48 h) in a propidium iodide (PI)-negative 
cell subset. As shown for the A549 cells, the highest 
induction of membranous CD70 was seen 24 h and 48 h 
after treatment with 7 µM of CDDP (Figure 2A). CD70 
protein levels were also significantly upregulated in a very 
strong (NCI-H1975) and very weak (NCI-H1650) CD70+ 
expressing cell line (Figure 2B). In line with these results, 
immunofluorescence demonstrated a marked induction of 
CD70 protein levels after treatment with CDDP compared 
to vehicle (Figure 2C). To demonstrate that the observed 
effect was attributed to increased transcription of CD70, 
CD70 mRNA levels were screened after treatment with 
vehicle or CDDP. Twenty-four hours after treatment, an 
average 1.4-, 4.3- and 4.0- fold increase of CD70 mRNA 
could be detected in CDDP-treated NCI-H1975, A549 and 
NCI-H1650 cells, respectively (Figure 2D). To examine 
whether changes in DNA methylation contributed to 
CDDP-induced CD70 overexpression, methylation of 4 CG 
pairs located between 581 and 288 base pairs upstream of 
the TNFSF7 locus, was analyzed using bisulphite-converted 
genomic DNA in NCI-H1975 cells treated with vehicle 
or 7 µM CDDP (Supplementary Materials and Methods 
Supplementary Table 1). As shown in Supplementary 
Figure 1, the induction of CD70 protein levels could not 
be attributed to variations in the methylation status of the 
CD70 promotor region in NSCI-H1975 cells. In summary, 
these data indicate that CDPP treatment induces CD70 
expression by increased levels of CD70 mRNA.
Increased tumor-specific CD70 protein levels 
after induction chemotherapy 
Next, the CDDP-induced expression of CD70 was 
examined in vivo using A549 tumor-bearing CD1 nude 
mice to verify the expression upon CDDP-treatment and the 
Figure 2: Changes in CD70 protein- and mRNA expression levels in response to CDDP-therapy. (A) A549 cells were treated 
with vehicle or CDDP (3.5 µM, 7 µM or 13 µM) for 24 h. CD70 expression levels were determined 1 h, 6 h, 24 h and 48 h after treatment. 
Graph represents ∆ mean fluorescence intensity (∆MFI) of three independent experiments; (B) NCI-H1975, A549 and NCI-H1650 cells 
were treated with vehicle or CDDP (7 µM) for 24 h. Graph represents ∆MFI of three independent experiments. In addition, representative 
histogram plots of vehicle- and CDDP-treated cells are displayed; (C) CD70 expression was measured by immunofluorescence (red) after 
treatment with vehicle or CDDP (7 µM) for 24 h in the A549 cells. Nuclei were stained by DAPI (blue); (D) CD70 mRNA levels were 
determined 24 h after treatment with vehicle or CDDP (7 µM). Graph represents relative mRNA levels in comparison to vehicle-treated 
cells. *P < 0.05, significant increase compared to vehicle.
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effects of multiple treatment regimens. Therefore, tumor-
bearing mice were treated with vehicle (0.9% NaCl), low 
(2.5 mg/kg) or high (5 mg/kg) doses of CDDP at day 0 and 
day 7. As shown in Figure 3, a high dose of CDDP (5 mg/
kg) resulted in a peak in CD70 expression two days’ post-
treatment. On the other hand, CD70 overexpression upon 
low doses of CDDP was only observed seven days’ post-
treatment. Interestingly, at day 9 we could observe stable 
CD70 overexpression upon low dose of CDDP (2.5 mg/kg) 
whereas a decrease was seen in the high-dose group. These 
findings indicate that the post-therapy increase in CD70 
expression was slightly delayed in the low treatment group 
but more stable over time. 
Combining CDDP with aCD70 significantly 
decreases tumor cell proliferation as opposed to 
single treatment regimens due to increased ADCC
We hypothesized that the significant accumulation 
of membranous CD70 upon CDDP-treatment could lead 
to an enhanced ADCC-effect of aCD70. To confirm 
this hypothesis, the ADCC potential of aCD70 in this 
combination regimen was evaluated in real-time using 
the xCELLigence RTCA system. Twenty-four hours after 
treatment of the cancer cells with medium doses of CDDP 
(24 h, 7 µM), natural killer (NK) cells (E/T=5/1) were 
cocultured with the cancer cells and treated with aCD70 
(48 h, 0.5 µM) or isotype control (48 h, 0.5 µM). In the 
CD70− cell line, NCI-H1650, the anti-proliferative effect 
of aCD70 in single treatment regimen was negligible 
as compared to isotype control (Figure 4A). Treatment 
with CDDP + isotype (CDDPi) on the other hand 
resulted in 26.34 ± 3.09% cell survival after 48 h as 
opposed to untreated cells. Interestingly, the combination 
of aCD70with medium doses of CDDP decreased 
proliferation significantly with an additional 12.99 ± 0.36% 
compared to CDDPi. In the weak CD70+ A549 cells, 
the ADCC-effect of aCD70 in monotherapy was more 
pronounced, resulting in 69.28 ± 0.02% and 81.09 ± 1.71% 
cell survival 24 h and 48 h post-treatment, respectively 
(Figure 4B). Yet again, the most significant decrease in cell 
survival was seen in the sequential combination regimen 
of CDDP and aCD70 (36.02 ± 0.25% (24 h) and 25.26 
± 0.04% (48 h) cell survival). In comparison to the other 
cell lines, the ADCC-effect of aCD70 in monotherapy was 
most pronounced in the strong CD70+ NCI-H1975 cells 
with only 36.87 ± 4.68% cell survival 48 h after treatment 
(Figure 4C). Even so, sequential administration of CDDP 
Figure 3: In vivo CD70 protein analysis upon CDDP-treatment. CD-1 nude mice were inoculated with A549 cells in the right 
hind leg. Tumor-bearing mice were randomly divided into 3 groups and treated intraperitoneally with vehicle (0.9% NaCl), low (2.5 mg/kg) 
or high (5 mg/kg) doses of CDDP on day 0 and day 7. Mice were sacrificed at different time points (Day 2, Day 7, Day 9) to evaluate the 
expression of CD70 by IHC. Figure shows representative sections of CD70 expression levels in all conditions. Mean CD70 percentages 
(N = 3; *N = 2) are depicted in every right corner. Magnitude 10× and 100×.
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and aCD70 resulted in a clear additional decrease in cell 
survival of 20.72 ± 3.34% and 43.51 ± 3.34% compared 
to single treatment of aCD70 or CDDP, respectively. 
To confirm cell death, the combination strategy in the 
NCI-H1975 cell line was also examined by the evaluation 
of caspase 3/5, using the incuCyte™ as displayed in 
Supplementary Figure 2. Here, cell death was most 
pronounced in the combination therapy, supporting our 
previous results. In conclusion, we have revealed strong 
efficacy of a combination regimen with medium doses of 
CDDP and aCD70 in all cell lines tested.
Strong efficacy of CDDP in combination with 
aCD70 under hypoxic conditions 
Hypoxia is an important contributor to the 
heterogeneity of the tumor microenvironment in solid 
tumors, driving adaptations which are essential for the 
survival and metastatic capabilities of tumor cells [11]. 
Therefore, experiments were also conducted under 
hypoxic conditions. Interestingly, we noticed a higher 
CD70 baseline expression under hypoxic conditions 
in all cell lines tested (data not shown). Likewise, our 
immunohistochemistry (IHC) data on an in vivo mice 
model demonstrated a strong CD70 overexpression on 
hypoxic regions of the tumor, as shown in Figure 5. 
Nonetheless the increased baseline CD70 expression 
under hypoxia, in vitro experiments demonstrated a 
similar induction of membranous CD70 levels 24 hours’ 
post-treatment with CDDP (24h, 7µM). In a final set of 
experiments, the ADCC potential of aCD70 after CDDP 
treatment was evaluated in the NCI-H1975 cell line using 
the xCELLigence RTCA system under reduced oxygen 
conditions (0.1–1% O2). In comparison to the treatment 
of the cells with CDDPi under normoxic conditions, the 
anti-proliferative effect was much less pronounced under 
hypoxia (Figure 4D). Forty-eight hours’ post-treatment, the 
greatest decrease in cell survival was seen after sequential 
treatment of CDDP and aCD70 with an additional decline 
of 41.44 ± 5.33% and 18.19 ± 5.33% compared to single 
treatment of aCD70 or CDDP, respectively. Hence, we can 
conclude that even under hypoxic conditions the use of 
CDDP can increase membrane CD70 expression levels 
and therefore enhance the ADCC-potential of aCD70. 
DISCUSSION
In this study, we are the first to demonstrate the 
induction of CD70 expression on the membrane of NSCLC 
cell lines upon CDDP treatment, a key drug for NSCLC 
treatment, even when administered at low doses. More 
importantly, the provision of CDDP treatment resulted 
in enhanced NK-cell mediated cellular cytotoxicity of 
ARGX-110, a CD70-specific mAb, in all cell lines tested. 
Previous studies of our group have demonstrated 
overexpression of the tumor antigen, CD70, on malignant 
cells in 16% of NSCLC patients and its absence on normal 
lung tissue, making it an attractive target for antibody-
based therapies [3]. Although our results demonstrated the 
potential of anti-CD70 therapy in NSCLC, this strategy 
would only be applicable to patients with CD70-positive 
tumors. However, here we have shown the increase of 
CD70 levels upon CDDP treatment, both on protein and 
mRNA level, thereby expanding the therapeutic window 
of anti-CD70 antibody treatment. Furthermore, we 
observed this overexpression in cells that survived CDDP 
treatment and therefore the induction of CD70 expression 
might also be linked with CDDP-resistance in NSCLC. 
In advanced ovarian cancer, Liu N et al. [12] described 
a similar phenomenon, with increased CD70 expression 
levels in patients resistant to CDDP-based adjuvant 
chemotherapies. However, the underlying mechanism of 
this overexpression was not investigated. In literature, it 
has been stated that the methylation status of CG pairs, 
located between 581 and 288 base pairs upstream of the 
TNFSF7 locus can influence CD70 transcription [13]. 
Because CDDP treatment can influence epigenetics, we 
have investigated these CG pairs upon CDDP treatment, 
but we did not notice any deviations in methylation 
status. As such, it is very likely that CDDP is affecting 
the regulation of transcription factors that bind to the 
CD70 promotor region such as AP-1 [14, 15]. Of note, 
CD70 upregulation was observed in cell lines with various 
p53 status, pointing towards a p53-independent mode 
of action. This is in line with previous experiments by 
Wisschusen et al. who demonstrated that radioinducibility 
of the CD70 gene did not require wild-type p53 activity 
and that this was not a response to genotoxic stress [16]. 
According to this study, the induction of CD70 upon 
irradiation was driving immune escape by the induction 
of apoptosis in peripheral blood mononuclear cells 
(PBMCs). The observed CDDP-mediated CD70 
expression might also pave the way towards immune 
escape as the CD70/CD27 axis has been linked with 
increased regulatory T cell counts in NSCLC specimens 
[3]. Therefore, our findings suggest that CD70-targeted 
therapies might be an interesting treatment choice to 
combine with CDDP to release the brakes on the immune 
system. In addition, it was demonstrated that some 
chemotherapeutic agents feature the ability to directly 
activate immune effectors such as NK cells [17]. In a 
clinical setting, such a synergistic combination therapy 
has already been proven effective with paclitaxel and 
trastuzumab [18]. Interestingly, CDDP treatment has 
previously shown to upregulate important ligands for 
NK cell-mediated eradication of tumor cells, including 
androgen receptor-UL16-binding protein 2 (ULBP2) and 
MHC class I chain-related molecule A and B (MICA A/B) 
in hepatocellular carcinoma and NSCLC, respectively 
[19, 20]. NK cells also play a pivotal role in mediating 
ADCC, whereby binding of their FcγRIII receptors to 
Fc portions of antibody-coated target cells stimulates the 
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release of cytotoxic molecules to kill the target cells. As 
such, we hypothesized that due to the favorable effects 
on NK cells and the increase in CD70 expression upon 
CDDP treatment, the sequential administration of CDDP 
and aCD70 could increase antibody-coverage and improve 
NK-mediated lysis of the tumor cells [4]. In this study, we 
revealed an enhanced efficacy of aCD70 upon treatment 
with low doses of CDDP by an increase in ADCC leading 
to tumor cell apoptosis. Moreover, by the induction 
of de novo CD70 expression upon CDDP treatment, 
Figure 4: Combining CDDP with aCD70 significantly decreases tumor cell proliferation due to increased ADCC. Left: 
NCI-H1650, A549, and NCI-H1975 cells were treated with vehicle or CDDP (24 h, 7 µM, 1st arrow). Cells were washed (2nd arrow) and 
aCD70 (0.5 µM) or isotype control (0.5 µM) was added to the medium in combination with NK cells (E/T=5/1) from healthy volunteers 
(3rd arrow). Cell survival was assessed up to 48 h after sequential treatment in 5 conditions: Vehicle, Isotype control (red), aCD70 (green), 
CDDP + isotype control (blue), CDDP + aCD70 (Purple). Left: Figure shows the well impedance of 1 representative donor, expressed 
by the cell index as a measure of viability, analyzed using the xCELLigence RTCA system. Cell indexes were normalized with the last 
point before compound addition. (A-B-C) Experiments were assessed under normoxic conditions. (D) Cells were seeded overnight under 
normoxic conditions. Thereafter experiments were assessed in an anaerobic chamber (O2: 0.1 – 1%). Lines represent the mean ± SEM. 
Right: Percentage of cell survival 12 h, 24 h and 48 h after sequential treatment. Bars represent the mean ± SEM. For all experiments, two 
replicates of the same condition were measured and run in parallel with NK cells from three different donors. *P < 0.05: significant decrease 
in cell survival compared to vehicle; **P < 0.05: significant decrease in cell survival compared to all other conditions.
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significant reduction in cell survival was also seen in cells 
that did not show any response to aCD70 in monotherapy. 
Hypoxia readily occurs in the majority of solid 
tumors, including NSCLC, and has been proven to 
contribute to tumor progression, metastasis and therapy 
resistance [21]. In addition, the natural killing capability of 
NK cells is compromised in a hypoxic microenvironment 
mediated through downregulation of important activating 
receptors [22]. Nevertheless, ADDC activity of NK cells 
is preserved under hypoxia [22]. Hence, our combination 
strategy of aCD70 and CDDP treatment was also explored 
under reduced oxygen levels. Firstly, a higher baseline 
CD70 expression was observed in vitro and in vivo 
under reduced oxygen levels in all cell lines. Likewise, 
it was recently described that CD70 expression is 
driven by hypoxia-inducible factor a in clear renal cell 
carcinoma [23]. We also found a strong induction of 
membranous CD70 expression upon CDDP treatment, 
which was similar to the effect of CDDP under normoxic 
condition. Finally, we could trigger efficient NK-cell 
mediated killing following treatment of CDDP and aCD70 
indicating that hypoxia is not a limiting factor for this 
promising combination strategy. 
MATERIALS AND METHODS
Cell lines and cell culture
The human NSCLC cell lines NCI-H1975, 
NCI-H1650, HCC827, LUDLU-1 and A549 were 
purchased from the American type cell culture collection 
(ATCC, Rockville MD, USA). The A549 cell line 
was cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin and 1% 
L-glutamine (Life Technologies, Merelbeke, Belgium). 
NCI-H1975, NCI-H1650, HCC827 and LUDLU-1 
cells were cultured in RPMI supplemented as described 
above with addition of 1mM sodium pyruvate (Life 
Technologies). Cells were grown as monolayers and 
were maintained in exponential growth at 5% CO2/95% 
air in a humidified incubator at 37°C to obtain normoxic 
conditions and in a humidified Bactron IV anaerobic 
chamber (Shel Lab, OR, USA, 1% O2, 5% CO2, 95% N2) 
to obtain hypoxic conditions. Cells used for experiments 
in hypoxic conditions were first grown overnight under 
normoxia to allow the cells to attach to the bottom. Cell 
cultures were regularly tested for absence of mycoplasma 
using the Mycoalert® Mycoplasma detection kit (Lonza, 
Verviers, Belgium) .
Purification of human natural killer (NK) cells
Human peripheral blood mononuclear cells (PBMC) 
were isolated by Ficoll-Paque Plus gradient separation 
(Amersham Biosciences, Uppsala, Sweden) from buffy 
coat preparations of healthy donors, provided by the Blood 
Transfusion Centre of Red Cross-Flanders (Mechelen, 
Belgium). Primary NK cells were negatively isolated 
from PBMC using the NK cell isolation kit (Miltenyi 
Biotec, Utrecht, The Netherlands; CD56+CD3- cells, purity 
88.1 ± 4.7%) as previously described. [3] In all experiments, 
NK cells of 3 different healthy donors were used.
Cytotoxicity assays
SRB assay. To evaluate cytotoxicity of CDDP, 
cells were seeded in 96-well plates, incubated overnight 
and treated for 24 h with CDDP (0–20 µM) as single 
agent. Forty-eight hours after treatment, cell monolayers 
were fixed with 10% trichloroacetic acid for 1 h at 4°C 
and stained with 100 μl 0.1% sulforhodamine B, as 
previously described [24]. The IC20, IC40 and IC60 value, 
the concentration of the drug that leads to 20%, 40% 
and 60% growth inhibition respectively, was calculated 
using the WinNonlin software (Pharsight, CA, USA). All 
experiments were performed at least in triplicate. 
xCELLigence. Real-time monitoring of cell 
viability was performed using the xCELLigence RTCA 
DP instrument (ACEA, Biosciences, San Diego, USA) 
as previously described. Shortly, target cells (T) were 
Figure 5: In vivo CD70 protein analysis in hypoxic regions. Tumor-bearing CD1-nude mice were sacrificed to evaluate CD70 
expression levels. Figure shows high CD70 expression levels in hypoxic regions surrounding necrotic areas. Magnitude 10× (left) and 100× 
(right).
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seeded at 3.5 × 103 cells/well, incubated overnight and 
exposed to 7 µM CDDP (IC20-value of A549 cell line) 
or vehicle (phosphate buffered saline (PBS) for 24 h. 
One day after CDDP treatment, cells were treated with 
ARGX-110, further mentioned as aCD70 (argenx BVBA, 
Zwijnaarde, Belgium, 0.5 µM) or isotype control (I5029, 
Sigma-Aldrich, 0.5µM) in combination with effector (E) 
NK cells (E/T=5/1). Real-time measurements ended 6 
days after initiation of the experiment. In each experiment, 
2 replicates of the same condition were used and run in 
parallel with NK cells from 3 different donors. 
CD70 expression analysis
Flow cytometry
Cells were treated with 7 µM CDDP or vehicle for 
24 h. Membrane CD70 expression was assessed by flow 
cytometry as previously described [3]. For experiments 
performed under hypoxic conditions, cells were fixed in 
4% Formaldehyde (10 min) prior to primary antibody 
incubation. The signal for aspecific binding (anti-human 
IgG phycoerythrin (PE)-conjugated antibody, eBioscience, 
San Diego, USA) was subtracted from the measured 
fluorescence intensities (=∆MFI). Dead cells were 
excluded from analysis by staining with PI. 
Immunofluorescence
Cells were treated with 7 µM CDDP or vehicle 
for 24 h. Cells were fixed in methanol, blocked with 
1% BSA/PBS for 1h and incubated overnight with anti-
CD70 (Clone 301731, 1/40, R&D systems, Abingdon, 
United Kingdom) at 4°C. Goat anti-mouse IgG secondary 
antibody, Alexa Fluor 555 conjugate (1/800, Thermo 
Fisher Scientific, Nepean, Canada) was used for 1 h as 
secondary antibody. Slides were counterstained with DAPI 
and mounted. Acquisition was performed by Evos Cell 
Imaging system (Thermo Fisher Scientific).
IHC
Twenty-seven tissue specimens were fixed in 4% 
formaldehyde for 6–18 h and paraffin embedded on a 
routine basis. CD70 IHC (Clone 301731 diluted 1/40 for 
20 min, R&D) was performed at room temperature on a 
DAKO autostainer Link 48 instrument using the Envision 
FLEX+ detection kit (DAKO) as previously described 
[3]. Scoring was performed by one pathologist, positive 
staining was assigned when tumor cells of any intensity 
and any CD70 distribution (membranous, cytoplasmic) 
showed specific CD70 staining. 
CD70 mRNA levels 
Real-time PCR (RT-PCR). Cells were treated with 7 
µM CDDP or vehicle for 24 h. RNA was isolated after 24 h 
of treatment using the TRIzol® method (Life Technologies). 
Total RNA-yield and quality were measured using the 
NanoDrop® ND-1000 (Thermo Fisher Scientific) and 
samples were stored at −80°C. RT-PCR was performed 
using the Power SYBR Green RNA-to-CT-Step kit (Applied 
Biosystems, Ghent, Belgium) on the LightCycler480 (Roche, 
Vilvoorde, Belgium) according to the manufacturer’s 
instructions with a total of 20 ng RNA. The optimal number 
and type of housekeeping genes (GAPD, RPLA13 and 
SDHA-1) were determined using the qbasePLUS software 
(Biogazelle, Zwijnaarde, Belgium) [24]. 
In vivo A549 xenograft model 
Female CD-1 athymic nude mice (N = 48, Charles 
River Laboratories, Calco, Italy) were purchased at an age 
of 6 weeks. Animals were group-housed in individually 
ventilated cages (3–8/cage) under specific pathogen free 
conditions with a 12 h day/night cycle and food and water 
ad libitum. A549 cells were harvested and resuspended 
in sterile PBS at a concentration of 4 × 107 viable cells 
per ml. CD-1 nude mice were inoculated with 100µl of 
cell suspension in the right hind leg. Experiments were 
initiated when tumors reached a volume of approximately 
100 mm³, ±4 weeks after inoculation. Tumor-bearing mice 
were randomly divided into 3 groups (N = 3) based on 
different treatment doses. CDDP was dissolved in PBS and 
applied intraperitoneally at low (2.5 mg/kg) or high (5 mg/
kg) doses on day 0 and day 7. The vehicle group (0.9% 
NaCl) and drug treatment groups were housed separately. 
To evaluate the expression of CD70 during treatment, 
tumor-bearing mice were sacrificed at different time 
points (Day 2, Day 7, Day 9) and tumors were embedded 
in paraformaldehyde for the assessment of CD70 IHC, as 
described above. The experimental protocol was approved 
by the Ethical Committee for Animal Testing (N° 2016–29) 
and all applicable institutional and European guidelines for 
the care and use of animals were followed.
Statistical analysis
Statistical significance for the in vitro experiments was 
determined by a one-way ANOVA test, followed by Tukey’s 
post hoc test whereby a p-value less than 0.05 was considered 
significant (two tailed). All analyses were conducted using 
SPSS version 23 (SPSS Inc., Chicago, IL, USA).
CONCLUSIONS
In this study, we have identified a novel mechanism 
to treat patients with non-small cell lung cancer. The 
administration of CD70-targeted therapy with the first-
line chemotherapeutic agent, Cisplatin, showed a strong 
synergistic effect, even when administered at low doses. 
Therefore, this combination regimen has the exciting 
potential to increase tumor-specific cytotoxicity and 
reduce drug-related side effects in patients with very little 
therapeutic options. Finally, due to the expression patterns 
Oncotarget74066www.impactjournals.com/oncotarget
of CD70, this study might also pave the way for improved 
treatment options in other tumor types. 
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